Merck, known as MSD outside the United States and Canada, and Orna Therapeutics, a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, have entered a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology.   Under the terms of the agreement, Merck will make an upfront payment to Orna of $150 million, which will be expensed by Merc...